Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Omeprazole

FDA-approved product (capsule, delayed rel pellets, oral), marketed as Omeprazole, Prilosec, Omeprazole Magnesium and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Omeprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Duodenal ulcer
  • Dyspepsia
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Infection
  • Peptic ulcer
  • Peptic ulcer disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Proton pump inhibitors
FDA pharmacologic class
Proton Pump Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Omeprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Omeprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU

    NCT07399054 · start 2026-08-23

    Registered record
    Registry ID
    NCT07399054
    Conditions
    Stress Ulcers; Reflux Episodes
    Interventions
    Esomeprazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-08-23
    Completion
    2027-02-28
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Ulcers; Reflux Episodes
    InterventionEsomeprazole
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Metronidazole- Versus Tinidazole-Based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

    NCT07746934 · start 2026-07-27

    Registered record
    Registry ID
    NCT07746934
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Metronidazole; Tinidazole 500mg; tetracyline; Bismuth Subcitrate; esomeprazole 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07-27
    Completion
    2027-12-27
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionMetronidazole; Tinidazole 500mg; tetracyline; Bismuth Subcitrate +1 more
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Study to Evaluate the Effects of Low-Fat Meal, High-Fat Meal and Omeprazole Enteric-Coated Tablets on the Pharmacokinetics of ABSK-011 Capsules in Healthy Participants

    NCT07700953 · start 2026-07-21

    Registered record
    Registry ID
    NCT07700953
    Conditions
    Healthy Participants
    Interventions
    ABSK-011 Capsules; omeprazole enteric-coated tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-07-21
    Completion
    2026-08-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionABSK-011 Capsules; omeprazole enteric-coated tablets
    PhasePhase 1
    Registry statusRecruiting

  • Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

    NCT07223671 · start 2025-12-31

    Registered record
    Registry ID
    NCT07223671
    Conditions
    Healthy Volunteers
    Interventions
    Repotrectinib; Metformin; Digoxin; Rosuvastatin; Bupropion; Flurbiprofen; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-12-31
    Completion
    2026-03-19
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionRepotrectinib; Metformin; Digoxin; Rosuvastatin +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants

    NCT06948006 · start 2025-04-23

    Registered record
    Registry ID
    NCT06948006
    Conditions
    Healthy Participants
    Interventions
    AZD4144; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-04-23
    Completion
    2025-06-27
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAZD4144; Omeprazole
    PhasePhase 1
    Registry statusCompleted

  • Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children

    NCT07086937 · start 2025-01-01

    Registered record
    Registry ID
    NCT07086937
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Nitazoxanide; Metronidazole; PPI; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-01-01
    Completion
    2025-06-30
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionNitazoxanide; Metronidazole; PPI; Clarithromycin
    PhaseNot applicable
    Registry statusCompleted

  • A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

    NCT06717269 · start 2024-11-30

    Registered record
    Registry ID
    NCT06717269
    Conditions
    Healthy Volunteer
    Interventions
    NX-5948; Esomeprazole; Placebo; Famotidine; Midazolam; Digoxin; Rosuvastatin; Quinidine; NX-5948
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-11-30
    Completion
    2026-05-01
    Enrolment
    223

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionNX-5948; Esomeprazole; Placebo; Famotidine +5 more
    PhasePhase 1
    Registry statusCompleted

  • An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

    NCT06686628 · start 2024-11-20

    Registered record
    Registry ID
    NCT06686628
    Conditions
    Dermatitis Atopic
    Interventions
    Amlitelimab; Midazolam; Caffeine; Metoprolol; Omeprazole; Warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-11-20
    Completion
    2026-04-02
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis Atopic
    InterventionAmlitelimab; Midazolam; Caffeine; Metoprolol +2 more
    PhasePhase 1
    Registry statusCompleted

  • Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding

    NCT05624229 · start 2023-10-01

    Registered record
    Registry ID
    NCT05624229
    Conditions
    Upper Gastrointestinal Hemorrhage
    Interventions
    Proton Pump Inhibitors; No Proton Pump Inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2023-10-01
    Completion
    2028-12-31
    Enrolment
    672

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUpper Gastrointestinal Hemorrhage
    InterventionProton Pump Inhibitors; No Proton Pump Inhibitors
    PhasePhase 4
    Registry statusNot yet recruiting

  • Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）

    NCT05870683 · start 2023-05-24

    Registered record
    Registry ID
    NCT05870683
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Tegoprazan; Amoxicillin; Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-05-24
    Completion
    2023-12-30
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionTegoprazan; Amoxicillin; Esomeprazole
    PhaseNot applicable
    Registry statusUnknown

  • A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

    NCT06105255 · start 2023-05-24

    Registered record
    Registry ID
    NCT06105255
    Conditions
    Healthy Male
    Interventions
    D-1553
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-05-24
    Completion
    2024-02-02
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male
    InterventionD-1553
    PhasePhase 1
    Registry statusCompleted

  • PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers

    NCT05582174 · start 2023-05-18

    Registered record
    Registry ID
    NCT05582174
    Conditions
    Upper GI Bleeding; Proton Pump Inhibitors
    Interventions
    Vonoprazan; esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-05-18
    Completion
    2028-07-03
    Enrolment
    594

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUpper GI Bleeding; Proton Pump Inhibitors
    InterventionVonoprazan; esomeprazole
    PhasePhase 4
    Registry statusRecruiting

  • A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

    NCT05392127 · start 2022-07-15

    Registered record
    Registry ID
    NCT05392127
    Conditions
    Rheumatoid Arthritis
    Interventions
    SHR0302 Tablets; Midazolam Maleate Tablets; Warfarin Sodium Tablets; Omeprazole Enteric Capsules; Vitamin K1 Tablets; Repaglinide Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-07-15
    Completion
    2022-08-18
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionSHR0302 Tablets; Midazolam Maleate Tablets; Warfarin Sodium Tablets; Omeprazole Enteric Capsules +2 more
    PhasePhase 1
    Registry statusCompleted

  • Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.

    NCT05432115 · start 2022-06-25

    Registered record
    Registry ID
    NCT05432115
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Tetracyclin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-06-25
    Completion
    2023-10
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionTetracyclin
    PhasePhase 4
    Registry statusUnknown

  • Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy

    NCT05070351 · start 2022-01-03

    Registered record
    Registry ID
    NCT05070351
    Conditions
    Hepatic Encephalopathy
    Interventions
    PPI deprescribing
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2022-01-03
    Completion
    2025-06-02
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy
    InterventionPPI deprescribing
    PhasePhase 1 / Phase 2
    Registry statusCompleted